Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort
Por:
Berenguer, J, Diez, C, Martin-Vicente, M, Mican, R, Perez-Elias, M, Garcia-Fraile, L, Vidal, F, Suarez-Garcia, I, Podzamczer, D, Del Romero, J, Pulido, F, Iribarren, J, Gutierrez, F, Poveda, E, Galera, C, Izquierdo, R, Asensi, V, Portilla, J, Lopez, J, Arribas, J, Moreno, S, Gonzalez-Garcia, J, Resino, S and Jarrin, I
Publicada:
1 nov 2021
Ahead of Print:
26 jun 2021
Resumen:
Objectives: We aimed to assess the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and factors associated with seropositivity and asymptomatic coronavirus disease 2019 (COVID-19) among people with HIV (PWH).
Methods: This was a cross-sectional study carried out within the cohort of the Spanish HIV Research Network. Participants were consecutive PWH with plasma collected from 1st April to 30th September 2020. We determined SARS-CoV-2 antibodies (Abs) in plasma. Illness severity (NIH criteria) was assessed by a review of medical records and, if needed, participant interviews. Multivariable logistic regression analysis was used to identify predictors of seropositivity among the following variables: sex, age, country of birth, education level, comorbidities (hypertension, chronic heart disease, diabetes mellitus, non-AIDS-related cancer, chronic kidney disease, cirrhosis), route of HIV acquisition, prior AIDS, CD4+ cell count, HIV viral load, nucleoside/nucleotide reverse transcriptase inhibitor (N [t]RTI) backbone, type of third antiretroviral drug, and month of sample collection.
Results: Of 1076 PWH (88.0% males, median age 43 years, 97.7% on antiretroviral therapy, median CD4+ 688 cells/mm(3), 91.4% undetectable HIV viral load), SARS-CoV-2 Abs were detected in 91 PWH, a seroprevalence of 8.5% (95%CI 6.9-10.3%). Forty-five infections (45.0%) were asymptomatic. Variables independently associated with SARS-CoV-2 seropositivity were birth in Latin American countries versus Spain (adjusted odds ratio (aOR) 2.30, 95%CI 1.41-3.76, p 0.001), and therapy with tenofovir disoproxil fumarate plus emtricitabine (TDF/FTC) versus tenofovir alafenamide (TAF)/FTC as the N(t)RTI backbone (aOR 0.49, 95%CI 0.26-0.94, p 0.031).
Conclusions: Many SARS-CoV-2 infections among PWH were asymptomatic, and birth in Latin American countries increased the risk of SARS-CoV-2 seropositivity. Our analysis, adjusted by comorbidities and other variables, suggests that TDF/FTC may prevent SARS-CoV-2 infection among PWH. (C) 2021 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.
Filiaciones:
:
Hosp Gen Univ Gregorio Maranon, IISGM, Madrid, Spain
Diez, C:
Hosp Gen Univ Gregorio Maranon, IISGM, Madrid, Spain
Martin-Vicente, M:
Ctr Nacl Microbiol ISCIII, Majadahonda, Spain
Mican, R:
Hosp Univ La Paz, IdiPAZ, Madrid, Spain
Perez-Elias, M:
Univ Alcala De Henares, Hosp Ramon y Cajal, IRYCIS, Madrid, Spain
Garcia-Fraile, L:
Hosp Univ La Princesa, Madrid, Spain
Vidal, F:
Univ Rovira & Virgili, Hosp Univ Tarragona Joan XXIII, IISPV, Tarragona, Spain
Suarez-Garcia, I:
Univ Europea Madrid, Hosp Univ Infanta Sofia, FIIB HUIS HHEN, San Sebastian De Reyes, Spain
Podzamczer, D:
Hosp Univ Bellvitge, Barcelona, Spain
Del Romero, J:
Ctr Sandoval, Madrid, Spain
Pulido, F:
Univ Complutense Madrid, Hosp Univ 12 Octubre, Imas12, Madrid, Spain
Iribarren, J:
Hosp Univ Donostia, II BioDonostia, San Sebastian, Spain
Gutierrez, F:
Univ Miguel Hernandez, Hosp Univ Elche, Elche, Spain
Poveda, E:
Galicia Hlth Res Inst IIS Galicia Sur Complexo Ho, SERGAS UVigo, Vigo, Spain
Galera, C:
Hosp Univ Virgen de la Arrixaca, Murcia, Spain
Izquierdo, R:
Ctr Nacl Epidemiol ISCIII, Madrid, Spain
Asensi, V:
Hosp Univ Cent Asturias, Oviedo, Spain
:
Hosp Gen Univ Alicante, Alicante, Spain
Lopez, J:
Hosp Gen Univ Gregorio Maranon, IISGM, Madrid, Spain
Arribas, J:
Hosp Univ La Paz, IdiPAZ, Madrid, Spain
Moreno, S:
Univ Alcala De Henares, Hosp Ramon y Cajal, IRYCIS, Madrid, Spain
Gonzalez-Garcia, J:
Hosp Univ La Paz, IdiPAZ, Madrid, Spain
Resino, S:
Ctr Nacl Microbiol ISCIII, Majadahonda, Spain
:
Ctr Nacl Epidemiol ISCIII, Madrid, Spain
hybrid, Green Published
|